

# Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects

Shailendra Kapoor

Mechanicsville, Richmond, VA, USA

## To the editor

I read with great interest the article by Andukuri et al in a recent issue of your journal.<sup>1</sup> The article makes compelling reading. Interestingly, research over the past few years has shown that in addition to its significant diabetic-modulating effects, alogliptin also exerts significant direct antiatherosclerotic effects.

For instance, alogliptin decreases plasma nonesterified fatty acid levels by 11%.<sup>2</sup> It simultaneously has an attenuating effect on serum triglyceride levels, decreasing them by almost 24%. Similarly, Monami et al in a recent meta-analysis reported that alogliptin is associated with a significant attenuation in total serum cholesterol.<sup>3</sup> Alogliptin also significantly decreases postprandial very low-density lipoprotein and chylomicron levels.<sup>4</sup> Alogliptin mediates its antiatherosclerotic effects by decreasing expression of interleukin-1 $\beta$  and interleukin-6, which is typically enhanced in diabetes.<sup>5</sup> It also has an attenuating effect on extracellular signal-regulated kinase-mediated expression of metalloproteinases 1 and 12.<sup>6</sup> This exerts a significant inhibitory effect on macrophage-modulated inflammation and thereby attenuates vascular atherosclerosis.

Interestingly, these hypolipidemic effects of alogliptin are markedly enhanced when used in combination with pioglitazone. For instance, alogliptin with adjunctive pioglitazone therapy decreases plasma nonesterified fatty acid levels by 25%–48% and serum triglyceride levels by 67%–77%.<sup>2,7</sup> Alogliptin clearly exerts significant antiatherosclerotic and hypolipidemic effects, and may go a long way towards attenuating atherosclerosis-related morbidity and mortality in patients with diabetes as well as the metabolic syndrome.

## References

1. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. *Diabetes Metab Syndr Obes.* 2009;2:117–126.
2. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. *Eur J Pharmacol.* 2009;602:448–454.
3. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. *Adv Ther.* 2012;29:14–25.
4. Eliasson B, Moller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. *Diabetologia.* 2012;55:915–925.
5. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. *J Cardiovasc Pharmacol.* 2011;58:157–166.

Correspondence: Shailendra Kapoor  
2300 E Cary St Richmond,  
VA 23223, USA  
Tel +1 804 2342345  
Fax +1 804 3454561  
Email shailendrakapoor@yahoo.com

6. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. *Atherosclerosis*. 2010;213:429–435.
7. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. *Br J Pharmacol*. 2009;157:415–426.

## Author's response

Marc Rendell

Division of Endocrinology, Department of Medicine,  
Creighton University School  
of Medicine, Omaha, NE

---

Correspondence: Marc Rendell  
Creighton Diabetes Center, 601 North 30th Street, Omaha, NE 68131,  
USA  
Fax +1 402 280 5655  
Email [rendell@asndi.com](mailto:rendell@asndi.com)

The letter by Dr Kapoor points out useful data in animal models. The current long-term cardiac outcome trials of alogliptin will be essential to determine the effect of this agent on the atherosclerotic process in man.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

### Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert

opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>